BioSpace News Archive

Grid Therapeutics , LLC today announced the initiation of a combination Phase 2 investigator-sponsored study of its lead asset, GT103.

VYNE Therapeutics Inc. today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference at the Boston Marriott Copley Place in Boston.

Oncocyte Corporation, a precision diagnostics company, announced that it has completed the sale of 70% of its ownership stake in wholly-owned subsidiary Razor Genomics to Dragon Scientific.

Oryzon Genomics, S.A. announced that it will host a virtual panel discussion, featuring Dr. Dyanna Phillips Domilici, Dr. med. Peter Hahn, and Dr. Olga Salamero, discussing the unmet medical needs in specific central nervous system and oncology diseases.

Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the Cowen Annual Health Care Conference.

QSAM Biosciences Inc. (OTCQB: QSAM) today announces the addition of the Ellis Fischel Cancer Center (EFCC) at the University of Missouri (MU) School of Medicine (SOM) as an upcoming clinical trial site to soon begin enrolling participants into the Phase 1 study evaluating CycloSam® for participants with multiple types of bone cancer that either originated in or has metastasized to the bone.

TransCode Therapeutics, Inc. today announced the signing of a non-binding letter of intent and a joint research and development agreement (JDA) with industrial biotechnology and genome editing expert, BRAIN Biotech AG.

Aquestive Therapeutics, Inc. today announced that it will report results for fourth quarter ended December 31, 2022, and provide an update on recent developments in its business after market close on Tuesday, March 7, 2023.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the start of a Phase 1 study evaluating its development program targeted at treating primary dysmenorrhea by delivering the active pharmaceutical ingredient diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), in a novel way.

ProPhase Labs, Inc. today announced that its wholly-owned subsidiary, ProPhase BioPharma, Inc. (PBIO), is initiating a randomized, placebo-controlled clinical trial of Equivir (OTC) to evaluate its effect on upper respiratory tract infections.